CTLA4 and melanoma: In melanoma, PD-1 and CTLA-4 inhibitory antibodies (nivolumab, pembrolizumab, and ipilimumab) have been approved as single agents or in combination for treatment of patients with unresectable stage III and distant metastatic disease [2,3].